Q3 2022 Results
Company overview
Financial review
2022 priorities
Appendix
References
Continuing core margin improvements for Group driven by IM
Innovative Medicines
Sandoz
Group
Net sales
change vs. PY
Q3 2022
Core operating
9M 2022
1
income
change vs. PY
Core margin
Core margin
change vs. PY
Net sales
change vs. PY
Core operating
income
change vs. PY
Core margin
Core margin
change vs. PY
(in % cc) 1
(in % cc) 1
1
(%)
(%pts cc)
(in % cc) 1
(in % cc) 1
(%)
(%pts cc) 1
4
7
38.1
1.0
5
6
37.1
0.5
4
-5
22.3
-2.2
6
5
21.9
-0.2
4
5
34.1
0.2
5
LO
6
33.4
0.5
IM - Innovative Medicines 1. Constant currencies (cc), core results are non-IFRS measures. An explanation of non-IFRS measures can be found on page 49 of the Condensed Interim Financial Report.
22 Investor Relations | Q3 2022 Results
ā NOVARTIS | Reimagining MedicineView entire presentation